News

Stockhead on MSN2d
ScoPo’s Powerplays: CSL leads a 5pc ASX health stocks rally
Morgans healthcare and life sciences expert Iain Wilkie fills in for Scott Power this week, covering what the health movers ...
Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly's Zepbound
An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...
J.P. Morgan Sees Strong Q2 for Eli Lilly, Maintains Overweight Rating
Eli Lilly and Company (NYSE:LLY) is one of the high-margin pharma stocks to buy now. Eli Lilly and Company (NYSE:LLY) is set ...
Investing Snacks6d
Eli Lilly’s Bold Step in Obesity Drug Research
Eli Lilly is advancing its Phase 2 clinical trial to test LY3841136 for weight management in obese and overweight adults.
ABP News on MSN5d
CBSE Pushes ‘Oil Boards’ In Schools To Tackle Obesity Crisis Among Students; Details Here
The Central Board of Secondary Education (CBSE) has issued a fresh directive urging schools to install 'Oil Boards' on campuses in an effort to cultivate healthy habits among students. The initiative, ...